tiprankstipranks
Trending News
More News >
Butterfly Network, Inc. (BFLY)
:BFLY
US Market

Butterfly Network (BFLY) AI Stock Analysis

Compare
1,900 Followers

Top Page

BFLY

Butterfly Network

(NYSE:BFLY)

Select Model
Select Model
Select Model
Neutral 59 (OpenAI - 4o)
Rating:59Neutral
Price Target:
$3.50
▲(71.57% Upside)
Butterfly Network's overall stock score reflects significant financial challenges, mitigated by positive technical indicators and strategic corporate developments. While the company shows potential through AI initiatives and new product launches, persistent profitability and cash flow issues remain key risks.
Positive Factors
Strategic Partnerships
The licensing deal with Midjourney enhances Butterfly's market reach and revenue streams, providing a stable income source and potential for growth through milestone payments.
AI Strategy and Product Development
New product launches and certifications strengthen Butterfly's market position, enhancing trust and expanding global reach, which supports long-term growth.
Revenue Growth
Achieving high-end revenue guidance indicates strong demand and effective sales strategies, supporting sustained growth and market presence.
Negative Factors
Negative Profitability
Persistent negative profitability challenges Butterfly's ability to reinvest in growth and innovation, potentially limiting its competitive edge and financial health.
Cash Flow Challenges
Ongoing cash flow issues strain liquidity and limit financial flexibility, posing risks to operational sustainability and strategic investments.
Operational Inefficiencies
Significant operational inefficiencies hinder profitability and resource allocation, affecting long-term operational effectiveness and competitive positioning.

Butterfly Network (BFLY) vs. SPDR S&P 500 ETF (SPY)

Butterfly Network Business Overview & Revenue Model

Company DescriptionButterfly Network, Inc. (BFLY) is a digital health company that specializes in revolutionizing medical imaging through its innovative handheld ultrasound technology. The company's core product is the Butterfly iQ, a pocket-sized ultrasound device that leverages advanced semiconductor technology and a proprietary software platform to deliver high-quality imaging at a fraction of the cost of traditional ultrasound machines. Butterfly Network operates in the healthcare sector, focusing on providing accessible and affordable diagnostic imaging solutions for a range of clinical applications.
How the Company Makes MoneyButterfly Network generates revenue primarily through the sale of its Butterfly iQ ultrasound devices and associated software subscriptions. The company operates on a direct sales model, targeting hospitals, clinics, and healthcare providers that require ultrasound imaging solutions. Additionally, Butterfly Network offers a subscription-based software service that provides users with access to advanced imaging features and cloud-based data storage, enhancing the functionality of their devices. Strategic partnerships with healthcare organizations and technology companies also contribute to revenue by expanding market reach and integrating their ultrasound solutions into existing healthcare systems.

Butterfly Network Key Performance Indicators (KPIs)

Any
Any
Revenue by Geography
Revenue by Geography
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Chart InsightsButterfly Network's U.S. revenue has shown a steady increase, but recent quarters reveal stagnation due to macroeconomic challenges and delays in large deals. International revenue, however, is gaining momentum, with a 19% increase driven by new product launches and geographic expansion. The company is strategically focusing on AI and software advancements to bolster growth, particularly in international markets, while navigating domestic uncertainties. This dual approach aims to capitalize on global opportunities and mitigate domestic risks, potentially enhancing long-term revenue stability.
Data provided by:The Fly

Butterfly Network Earnings Call Summary

Earnings Call Date:Oct 31, 2025
(Q3-2025)
|
Next Earnings Date:Mar 04, 2026
Earnings Call Sentiment Neutral
The earnings call presented a mixed picture with notable achievements in revenue growth and AI strategy, counterbalanced by challenges related to macroeconomic factors and inventory write-offs. Despite delays in enterprise deals, the company remains optimistic about future prospects with new product developments and market expansion.
Q3-2025 Updates
Positive Updates
Revenue Growth and High-End Guidance
Butterfly Network reported third quarter 2025 results at the higher end of revenue guidance with a 5% growth over the prior year, primarily driven by higher average selling prices and increased volume in the U.S.
AI Strategy and Milestones
Butterfly's AI strategy accelerated in Q3 with the POCUS CARE trial highlighting real-world impact, improving clinical management in 35% of cases, reducing hospital length of stay by 30%, and generating over $750,000 in cost savings.
Launch of New Products and Certifications
The launch of HeartFocus and ISO 27001 certifications strengthened Butterfly's position as a trusted partner, enhancing enterprise readiness and expanding global reach.
Development of Next-Gen Chip Technology
Completion of the P5.1 chip development with MEMS capabilities and ongoing development of Apollo AI chip expected to enhance ultrasound processing and AI capabilities.
Negative Updates
Government Shutdown and Macro Challenges
The federal government shutdown posed potential risks for regulatory processing delays and deal timing, while macroeconomic factors led to customer purchase delays.
Inventory Write-Off Impacting Gross Margin
A noncash write-off of excess inventory related to previous generation chips resulted in a negative gross margin of 17.5% compared to 59.5% in the prior year.
Delayed Enterprise and Hospital Deals
Several large deals were delayed due to macroeconomic factors, impacting U.S. hospital and enterprise channels and contributing to a softer quarter.
Company Guidance
During the Butterfly Network Third Quarter 2025 Earnings Conference Call, Interim CFO Megan Carlson and CEO Joseph DeVivo provided guidance highlighting several key metrics. The company reported third-quarter revenue of $21.5 million, reflecting a 5% growth over the prior year, driven by higher average selling prices and increased volume in the U.S. and international markets. Gross margin, excluding a noncash inventory write-off, increased to 63.9% from 60% in the previous year. The company maintained its full-year revenue guidance of $91 million to $95 million and adjusted EBITDA loss guidance of $32 million to $35 million. Butterfly Network emphasized its strategic initiatives, including the anticipated launch of its next-gen enterprise software, Compass AI, and the development of the P5.1 chip, which is expected to surpass current handheld devices in performance. The company also highlighted the successful integration of AI tools in clinical settings, leading to significant cost savings and improved patient management, as evidenced by the POCUS CARE trial results published in JAMA. Despite macroeconomic headwinds and delayed purchase decisions, Butterfly Network remains optimistic about its growth prospects in 2026.

Butterfly Network Financial Statement Overview

Summary
Butterfly Network faces significant financial challenges, with unprofitability and negative cash flows being major concerns. Despite modest revenue growth and a strong gross profit margin, the company struggles with operational inefficiencies and cash management issues. The balance sheet shows low leverage, but persistent losses pose risks to future stability.
Income Statement
40
Negative
Butterfly Network has shown modest revenue growth with a year-over-year increase of approximately 4.35% in the TTM. However, the company is currently unprofitable with a negative net profit margin of -75.57% and a negative EBIT margin of -81.35%, indicating significant operational challenges. The gross profit margin is positive at 60.65%, suggesting some strength in cost management, but overall profitability remains a concern.
Balance Sheet
50
Neutral
The company's balance sheet reflects a moderate level of stability with a debt-to-equity ratio of 0.08, indicating low leverage. The equity ratio is relatively strong at 75.27%, demonstrating a solid equity base relative to total assets. However, the company has been consistently recording negative net income, which adversely affects return on equity, currently not calculable due to negative net income.
Cash Flow
45
Neutral
Butterfly Network's cash flow situation is challenging, with negative free cash flow and operating cash flow in the TTM. Despite a reduction in negative free cash flow compared to the previous period, the company continues to experience cash outflows from operations, affecting its liquidity position. The operating cash flow to net income ratio is not favorable, reflecting the need for better cash management strategies.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue88.45M82.06M65.90M73.39M62.56M46.25M
Gross Profit38.25M48.83M16.86M39.46M17.05M-61.22M
EBITDA-69.67M-60.92M-123.04M-162.74M-29.55M-160.25M
Net Income-79.87M-72.49M-133.70M-168.72M-32.41M-162.75M
Balance Sheet
Total Assets290.00M256.08M304.27M417.57M571.97M147.19M
Cash, Cash Equivalents and Short-Term Investments144.23M88.78M134.64M237.81M422.84M60.21M
Total Debt21.03M22.84M25.03M31.89M29.08M53.89M
Total Liabilities86.17M87.25M84.22M92.21M124.27M148.19M
Stockholders Equity203.83M168.83M220.05M325.36M447.69M-994.00K
Cash Flow
Free Cash Flow-27.52M-44.40M-104.60M-187.42M-197.06M-84.08M
Operating Cash Flow-24.85M-41.71M-98.82M-169.12M-189.19M-81.70M
Investing Cash Flow-2.67M-2.66M70.41M-93.78M-9.87M-2.38M
Financing Cash Flow76.74M-1.50M228.00K2.88M565.69M54.28M

Butterfly Network Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.04
Price Trends
50DMA
2.61
Positive
100DMA
2.16
Positive
200DMA
2.21
Positive
Market Momentum
MACD
0.23
Negative
RSI
65.90
Neutral
STOCH
69.13
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BFLY, the sentiment is Positive. The current price of 2.04 is below the 20-day moving average (MA) of 3.11, below the 50-day MA of 2.61, and below the 200-day MA of 2.21, indicating a bullish trend. The MACD of 0.23 indicates Negative momentum. The RSI at 65.90 is Neutral, neither overbought nor oversold. The STOCH value of 69.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BFLY.

Butterfly Network Risk Analysis

Butterfly Network disclosed 48 risk factors in its most recent earnings report. Butterfly Network reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Butterfly Network Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
$619.90M66.704.97%1.58%
61
Neutral
$786.43M-14.63-59.78%
59
Neutral
$899.26M-10.64-41.42%16.04%28.91%
52
Neutral
$428.07M-8.73-12.67%19.90%-57.90%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
50
Neutral
$512.49M-7.11-13.95%4.14%-45.29%
45
Neutral
$163.76M-51.63%7.90%19.92%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BFLY
Butterfly Network
3.56
0.47
15.21%
VREX
Varex Imaging
12.29
-1.87
-13.21%
KIDS
OrthoPediatrics
17.07
-5.31
-23.73%
BVS
Bioventus
7.49
-3.18
-29.80%
TMCI
Treace Medical Concepts
2.57
-4.39
-63.07%
CBLL
Ceribell, Inc.
21.20
-5.72
-21.25%

Butterfly Network Corporate Events

Business Operations and Strategy
Butterfly Network Signs Licensing Deal with Midjourney
Positive
Nov 18, 2025

On November 17, 2025, Butterfly Network, Inc. entered into a Co-Development and Licensing Agreement with Midjourney, Inc. This agreement grants Midjourney an exclusive license to use Butterfly’s ultrasound-on-chip technology for a specified field of use. Midjourney will pay Butterfly a one-time fee of $15 million and an annual license fee of $10 million, with additional payments possible upon reaching certain milestones. The agreement, which lasts five years, includes confidentiality and intellectual property provisions, and allows Midjourney to upgrade its license under certain conditions.

Executive/Board ChangesBusiness Operations and Strategy
Butterfly Network Appoints New CFO John Doherty
Positive
Oct 9, 2025

On October 9, 2025, Butterfly Network announced the appointment of John Doherty as Executive Vice President and Chief Financial Officer, effective December 8, 2025. Doherty brings over 25 years of financial leadership experience, having previously held significant roles at Kaltura, Magic Leap, and Verizon Communications. His expertise in financial strategy and transformative transactions is expected to support Butterfly’s growth and shareholder value. Megan Carlson, the Interim CFO, will resume her role as Chief Accounting Officer. This leadership change is part of Butterfly’s strategic efforts to strengthen its financial operations and continue its momentum in the digital health sector.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 09, 2025